

ASX Release

Oventus Brisbane Investor Lunch

Brisbane, Australia 1st February 2018: Oventus Medical Ltd (ASX: OVN) is pleased to invite shareholders and investors to attend a lunch presentation at Tattersall's Club in Brisbane at 12:30 pm on Friday 9th February 2018 where Clinical Director Dr Chris Hart will provide an update on product developments and our plans for 2018.

When: Friday, 9th February
Time: 12:30 pm for 1 pm presentation followed by Q&A, concludes by 3 pm
Where: [Tattersall's Club](#), Holdway Room, Tattersall's Arcade, 215 Queen St, Brisbane
Dress code: Business attire

Please **RSVP** for catering and logistical purposes by **Tuesday, 6th February** to reception@oventus.com.au or call 1300 533 159.

Sandwich wraps and beverages are available from 12:30 pm. Please make your **dietary requirements** known via the RSVP.

Discounted parking tickets are available via Queens Plaza or the Wintergarden car park. Ask the Tattersall's Concierge for details (T: 07 3319 5001).

—ENDS—

About Oventus

Oventus is a Brisbane, Australia, based medical device company that has commercialized and brought to market a new **sleep treatment platform** for the treatment of sleep apnoea and snoring that enhances the treatment outcomes of both oral appliance therapy and CPAP therapy through increased efficacy and greater adherence.

Oral appliance: Oventus' unique and patented 'Airway Technology' incorporated into an oral appliance, the O₂Vent™, bypasses multiple levels of breathing obstruction including the nose, soft palate and tongue.

Our appliances are particularly designed for sufferers with nasal obstructions, soft palate collapse and who consequently tend to breathe through their mouth while sleeping.

In action, when nasal obstruction is present, breathing is supplemented through the O₂Vent™'s integrated 'Airways' delivering air to the back of the mouth while maintaining an oral seal, stabilizing

the tongue base, bypassing obstructions in the nose and soft palate and reducing the collapsibility of the upper airway. However, when the nose is unobstructed, the O₂Vent™ allows for natural nasal breathing.

‘O₂Vent™ Connect’ Positive Airway Pressure (PAP) Connection: Severe sleep apnoea sufferers who have traditionally used a CPAP machine and full facemask can use Oventus’ O₂Vent™ oral appliance to interface with CPAP reducing operating pressure by around 66%, eliminating the need for straps and allowing physiologic mouth breathing while delivering CPAP. This has allowed for a re-design of the CPAP delivery system which is far less intrusive (without full face mask and straps), called the ‘O₂Vent™ Connect’.

Oventus’ O₂Vent™ Connect’ attaches to the front of the O₂Vent™, thereby doing away with the full face mask, while bringing air from the CPAP machine to the nasal opening at lower pressure.

Clinical trials: Over 50 patients to date have shown Oventus’ O₂Vent™ is successful in treating Obstructive Sleep Apnoea (OSA) by an additional 30-50% and that snoring was either eliminated or significantly reduced, when compared to mandibular or “jaw” advancement oral appliances which primarily reduce tongue based breathing obstruction. The positive results included those sufferers who had nasal obstructions and mainly breath through the mouth.

Market: According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.¹

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, however many patients have difficulty tolerating CPAP² due to discomfort caused from high operating pressure and low tolerance for a full face mask.

The Oventus oral appliance ‘Airway Technology’ in the O₂Vent™ when incorporated with Oventus’ ‘O₂Vent™ Connect’ allows sufferers to breathe physiologically through the mouth or through the nose whilst simultaneously delivering CPAP. Mild sufferers are able to solely wear the O₂Vent™ oral appliance.

Further information can be found on our website: <http://oventus.com.au/how-it-works/>.

¹ Deloitte Access Economics. *Reawakening Australia: the economic cost of sleep disorders in Australia, 2010. Canberra, Australia.*

² Beecroft, et al. *Oral continuous positive airway pressure for sleep apnea; effectiveness, patient preference, and adherence. Chest 124:2200–2208, 2003.*